恩扎鲁胺
前列腺癌
雄激素剥夺疗法
医学
雄激素受体
雄激素
肿瘤科
癌症
内科学
癌症研究
激素
作者
Yuanyuan Wang,Jiyuan Chen,Zhengjie Wu,Weihong Ding,Shen Gao,Yuan Gao,Chuanliang Xu
摘要
Prostate cancer is the second most common malignancy in men and androgen deprivation therapy is the first‐line therapy. However, most cases will eventually develop castration‐resistant prostate cancer after androgen deprivation therapy treatment. Enzalutamide is a second‐generation androgen receptor antagonist approved by the Food and Drug Administration to treat patients with castration‐resistant prostate cancer. Unfortunately, patients receiving enzalutamide treatment will ultimately develop resistance via various complicated mechanisms. This review examines the emerging information on these resistance mechanisms, including androgen receptor‐related signalling pathways, glucocorticoid receptor‐related pathways and metabolic effects. Notably, lineage plasticity and phenotype switching, gene polymorphisms and the relationship between microRNAs and drug resistance are addressed. Furthermore, potential therapeutic strategies for enzalutamide‐resistant castration‐resistant prostate cancer treatment are suggested, which can help discover more effective and specific regimens to overcome enzalutamide resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI